The metabolic dysfunction that characterizes obesity and type 2 diabetes mellitus affects not only the heart and kidneys, but also the liver. Although lifestyle modification remains the cornerstone in the management of metabolic liver diseases, the field has progressed this year, with a new definition, validation of non-invasive biomarkers and numerous clinical trials.

中文翻译：

---

NAFLD 和 NASH 治疗的关键一年

肥胖和2型糖尿病的代谢功能障碍不仅影响心脏和肾脏，还影响肝脏。尽管改变生活方式仍然是代谢性肝病治疗的基石，但今年该领域取得了进展，出现了新的定义、非侵入性生物标志物的验证和大量的临床试验。